Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...